Latest News

Latest News

Weekly News Roundup | 14 September 2026

Weekly News Roundup | 14 September 2026

Life science news 14 September 2026: two US approvals for rare diseases, a landmark antibody-drug conjugate readout, and two UK moves on pharmacy access and AI oversight. Scholar Rock’s Isembyld won FDA approval, described by the agency as the first SMA therapy to...

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

UK Expertise: Faster Cancer Diagnosis and Cleaner Energy

UK Expertise: Faster Cancer Diagnosis and Cleaner Energy

British research expertise to deliver faster cancer diagnosis and cleaner energy Major new backing for medical imaging centres across the UK alongside tidal energy testing expansion in Orkney and cutting-edge materials. From:  Department for Science, Innovation and...

read more
NIH Scientists Pioneer “Digital Twin” of Eye Cells

NIH Scientists Pioneer “Digital Twin” of Eye Cells

NIH Scientists Pioneer “Digital Twin” of Eye Cells: A New Frontier in Treating Age-Related Macular Degeneration In a landmark achievement for computational biology and ophthalmology, researchers at the National Institutes of Health (NIH) have announced the development...

read more
AuDHD: Rethinking the Overlap Between Autism and ADHD

AuDHD: Rethinking the Overlap Between Autism and ADHD

A Diagnostic Separation That Shaped a Generation For most of the modern history of psychiatry, autism and ADHD were treated as mutually exclusive conditions. Clinicians were trained to look for one or the other. Until the publication of DSM-5 in 2013, a dual diagnosis...

read more
FDA Approves Commercial Manufacturing at Rezon Bio

FDA Approves Commercial Manufacturing at Rezon Bio

Rezon Bio announces that its Warsaw-Duchnice facility has received approval from the U.S. Food and Drug Administration (FDA) for the commercial manufacturing of a biosimilar. This milestone represents an important step in the continued development of Rezon Bio's...

read more
Uniphar | Clinical merges with BMclinical

Uniphar | Clinical merges with BMclinical

Leading global healthcare services provider Uniphar announces a strategic merger between Uniphar | Clinical and BMclinical, reinforcing Uniphar | Clinical’s integrated clinical supply offering and solidifying its position as a trusted partner to pharmaceutical and...

read more
UK Expertise: Faster Cancer Diagnosis and Cleaner Energy

UK Expertise: Faster Cancer Diagnosis and Cleaner Energy

British research expertise to deliver faster cancer diagnosis and cleaner energy Major new backing for medical imaging centres across the UK alongside tidal energy testing expansion in Orkney and cutting-edge materials. From:  Department for Science, Innovation and...

read more
NIH Scientists Pioneer “Digital Twin” of Eye Cells

NIH Scientists Pioneer “Digital Twin” of Eye Cells

NIH Scientists Pioneer “Digital Twin” of Eye Cells: A New Frontier in Treating Age-Related Macular Degeneration In a landmark achievement for computational biology and ophthalmology, researchers at the National Institutes of Health (NIH) have announced the development...

read more
AuDHD: Rethinking the Overlap Between Autism and ADHD

AuDHD: Rethinking the Overlap Between Autism and ADHD

A Diagnostic Separation That Shaped a Generation For most of the modern history of psychiatry, autism and ADHD were treated as mutually exclusive conditions. Clinicians were trained to look for one or the other. Until the publication of DSM-5 in 2013, a dual diagnosis...

read more
FDA Approves Commercial Manufacturing at Rezon Bio

FDA Approves Commercial Manufacturing at Rezon Bio

Rezon Bio announces that its Warsaw-Duchnice facility has received approval from the U.S. Food and Drug Administration (FDA) for the commercial manufacturing of a biosimilar. This milestone represents an important step in the continued development of Rezon Bio's...

read more
Uniphar | Clinical merges with BMclinical

Uniphar | Clinical merges with BMclinical

Leading global healthcare services provider Uniphar announces a strategic merger between Uniphar | Clinical and BMclinical, reinforcing Uniphar | Clinical’s integrated clinical supply offering and solidifying its position as a trusted partner to pharmaceutical and...

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

AI-Enabled Pathology: De-risking Oncology Drug Development

AI-Enabled Pathology: De-risking Oncology Drug Development

Today, oncology drug development continues to experience the highest attrition rates across therapeutic areas[1]. Despite major advances in molecular profiling and biomarker-driven strategies, a significant proportion of oncology clinical trials still fail, often due...

read more
Why Sugar May Matter More Than We Thought

Why Sugar May Matter More Than We Thought

A New Energy-Centered Model of Metabolic Disease For decades, sugar has been framed as a problem of excess. Too many calories. Too many insulin spikes. Too much sweetness in the modern diet. That framing has shaped public health guidance, food reformulation, and...

read more
RCM Efficiency: Solving Insurance Denials & Margin Pressure

RCM Efficiency: Solving Insurance Denials & Margin Pressure

Insurance Denials and Revenue Cycle Inefficiencies Are Becoming a Primary Driver of Hospital Financial Strain U.S. hospitals are entering the next fiscal cycle under sustained financial pressure, and insurance denials have emerged as one of the most consequential, yet...

read more

Further News

How Clinical Research Is Transforming the Future of Sarcoma Care

Rare cancers present one of the greatest challenges in modern oncology. Individually uncommon but collectively accounting for around one in five cancer diagnoses worldwide, they have historically attracted less research funding, fewer clinical trials and limited...

Weekly News Roundup | 03 August 2026

Life science news 3 August 2026: argenx pays $2.2 billion for what it calls a first-in-class anti-CD122 antibody, Johnson & Johnson strikes agreements worth up to $3.5 billion with in vivo CAR-T developer Sail Biomedicines, and GSK launches a £1.9 billion savings...

Personalized Cancer Care: How the Immune System is Reshaping Oncology

Immuno-oncology is not a new frontier, and for years, therapies like checkpoint inhibitors have reshaped how we treat certain cancers. While early approaches established that the immune system could fight cancer, the field has seen both major breakthroughs and clear...

FDA PreCheck Program: Seven Companies Chosen to Reshape US Manufacturing

The United States Food and Drug Administration has selected seven pharmaceutical and biotechnology companies for its FDA PreCheck Program, a pilot initiative designed to accelerate the establishment of new domestic drug manufacturing facilities. Announced on 7 August...

Retatrutide Phase 3 Data: Record Weight Loss, Unanswered Questions

Retatrutide, Eli Lilly’s investigational triple hormone receptor agonist, has now reported positive results across five Phase 3 trials. In the pivotal TRIUMPH-1 obesity study, participants on the highest dose lost an average of 28.3% of their body weight at 80 weeks,...

Responsible AI in Healthcare: Building Trust for Clinical Innovation

Artificial intelligence (AI) is rapidly transforming healthcare, moving beyond research laboratories into hospitals, clinics, and public health systems worldwide. Today, AI supports clinicians in areas such as medical imaging, clinical documentation, decision support,...

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...

Clinical Trials Roundup | 31 July 2026

An FDA advisory committee votes against Capricor Therapeutics' deramiocel in Duchenne muscular dystrophy cardiomyopathy, Pfizer's ritlecitinib meets its co-primary endpoints in two Phase 3 nonsegmental vitiligo trials, Karyopharm Therapeutics' selinexor misses its...

The Security Blind Spot in Life Science Digitalization

The life sciences sector is in the midst of a digital transformation that most security teams were not built to handle. AI-driven drug discovery platforms, cloud-connected lab equipment, genomic databases, and real-time patient data pipelines are creating attack...

Making AI Work in a Regulated Medtech Industry

For several years, AI has been viewed as one of the biggest opportunities for the medtech sector. With an industry survey finding that 91% of leaders were enthusiastic about its potential, early conversations centred on how it could transform healthcare delivery and...

Measuring the Human Variables Healthcare Systems Continue to Miss

Healthcare organizations have never had more data available to them. Leaders monitor patient satisfaction scores, staffing ratios, productivity, quality indicators, denial rates, wait times, and length of stay. The dashboards are sophisticated, the reporting cadence...

Have We Lost the Plot? Why Life Sciences Can’t Let AI Become the Mission

It’s impossible to escape the topic of AI right now. AI hype in life sciences now dominates every boardroom, industry conference, pitch deck and earnings call. But we’ve seen this movie before. A decade ago, the topic was the cloud, and it, too, was everywhere -...

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.

See More Articles

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.